SFRP1 and pulmonary fibrosis: In pulmonary fibrosis, hypermethylation‐induced silencing of SFRP1 correlates with increased disease severity, while treatment with a DNA methyltransferase inhibitor 5‐aza‐2′‐deoxycytidine (5‐aza) restores their expression and improves lung function [237], suggesting a protective role for SFRP1.